|
|
Article: Antigen Express Announces Phase I SBIR Grant for Development of MHC Class II Enhanced Prostate Cancer Cell Vaccine.
- Article from:
- PR Newswire
- Article date:
- April 5, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WORCESTER, Mass., April 5 /PRNewswire/ --
Antigen Express, Inc. (AgExp) today announced that it has received a $192,000 Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), to support development of a novel prostate cancer cell vaccine based on the modulation of MHC Class II molecule expression. This method is also being applied in the development of direct intra-tumoral therapies, DNA vaccines, and dendritic cell based therapeutics.
Antigen Express researchers have shown that cancer cells expressing MHC Class II molecules can serve as potent vaccines for the treatment of cancer when the Ii (Invariant Chain) ...